Abstract
BackgroundAnti-TNFα therapy is routinely used in several rheumatic diseases in last fifteen years. However, these drugs have also raised new problems, particularly the increased risk of reactivation of latent tuberculosis...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
